U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Dec 16 13:45:31 UTC 2023
Edited
by admin
on Sat Dec 16 13:45:31 UTC 2023
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
0JSR7Z0NB6
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
AMIVANTAMAB
INN  
Official Name English
IMMUNOGLOBULIN G1 (413-LYSINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR) (HUMAN MONOCLONAL JNJ-61186372 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL JNJ-61186372 .KAPPA.-CHAIN, (234->228'),(237->231')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (411-A
Common Name English
Amivantamab [WHO-DD]
Common Name English
CNTO-4424
Code English
AMIVANTAMAB [JAN]
Common Name English
amivantamab [INN]
Common Name English
JNJ-61186372
Code English
ANTI-EGFR/C-MET BISPECIFIC ANTIBODY JNJ-61186372
Common Name English
JNJ-611
Code English
Classification Tree Code System Code
NCI_THESAURUS C1454
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
Code System Code Type Description
FDA UNII
0JSR7Z0NB6
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
PRIMARY
NCI_THESAURUS
C124993
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
PRIMARY
WIKIPEDIA
Amivantamab
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
PRIMARY
RXCUI
2549199
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
PRIMARY
DAILYMED
0JSR7Z0NB6
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
PRIMARY
INN
11030
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
PRIMARY
CAS
2171511-58-1
Created by admin on Sat Dec 16 13:45:31 UTC 2023 , Edited by admin on Sat Dec 16 13:45:31 UTC 2023
PRIMARY
From To
1_22 1_96
1_152 1_208
1_228 3_214
1_234 2_228
1_237 2_231
1_269 1_329
1_375 1_433
2_22 2_96
2_146 2_202
2_222 4_214
2_263 2_323
2_369 2_427
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_305
N 2_299
Related Record Type Details
TARGET -> INHIBITOR
BINDING
Kd
TARGET -> INHIBITOR
BINDING
Kd
INHIBITOR -> TARGET
Approved for treatment of EGFR EXON 20 insertions mutations in NSLC
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL